A dual GLP-1 and GIP receptor agonist used for type 2 diabetes and obesity, enhancing insulin secretion, suppressing glucagon, and promoting weight loss.
Li. Xuan X; Cao. Dachuang D; Sapin. Helene H; Wang. Fangyu F; Hunter Gibble. Theresa T; Raibulet. Ne...
The study shows that tirzepatide causes big weight loss (about 20% of body weight) in people with obesity, no matter how fit they start out, and it especially boosts physical function in those who were the least active or had the poorest health at the start. The improvement in function isn’t just from losing weight – there’s an extra benefit that seems to come directly from the drug.
This review looks at how safe and tolerable GLP‑1 drugs like tirzepatide are. It confirms they work well for blood sugar, weight loss, and heart health, but they can cause stomach problems, gallbladder issues, eye changes, and rare serious events. The paper also gives tips on how to start doses, watch for side effects, and what to do if problems appear, making it easier for DIY health enthusiasts to use these drugs safely.
Switching from a 1 mg weekly dose of semaglutide to tirzepatide, and quickly moving up to the 10 mg dose, lowered blood sugar (HbA1c) by about 0.7% in three months, with a hint of weight loss, while the lower 7.5 mg dose didn’t show clear benefits.
Müller Alves. Klara K; Teixeira da Silva. Manoela M; Kramer. Caroline Kaercher CK; Viana. Lucia...
A review of 10 clinical trials shows that drugs that activate the GLP‑1 receptor (like semaglutide and liraglutide) reliably cut weight, belly size, and blood sugar in people with mental‑health conditions who are also overweight, and they do so with only mild stomach upset.
Al Ozairi. Ebaa E; Irshad. Mohammad M; Alkandari. Jumana J; Sojan. Litty L; Alroudhan. Dherar D; Alo...
In a real‑world study of people with type 1 diabetes and obesity, tirzepatide caused the biggest weight drop (about 11% of body weight) over a year, with modest improvements in blood sugar and no severe low‑blood‑sugar or ketoacidosis events. Semaglutide and liraglutide also helped weight loss but a bit less. These drugs could be useful as add‑on treatments for weight control in T1D, but they’re not officially approved for this use yet.
A study in people who are overweight but don’t have diabetes found that tirzepatide helped them lose more weight over about a year and a half than the already‑popular drug semaglutide. The trial lasted 72 weeks and showed a clear advantage for tirzepatide without major safety concerns, suggesting it could be a stronger tool for weight‑loss and metabolic health.
Sabatella. Lucas L; Ortega. Patricia M PM; Azcárate. Víctor Valentí VV; Sastre. Ferna...
A big analysis of 30 trials shows that weight‑loss surgery still beats drugs at shrinking belly fat and improving blood sugar, but the new dual drug tirzepatide comes close. In studies that looked only at tirzepatide, it wasn’t significantly worse than surgery, meaning it could be a powerful non‑surgical tool for people wanting big weight drops and better metabolism.
Malhotra. Atul A; Grunstein. Ronald R RR; Azarbarzin. Ali A; Sands. Scott A SA; Dang. Xiangnan X; Ch...
Tirzepatide, a weekly injection that targets two gut hormones, not only helps people lose weight but also improves sleep apnea. In the SURMOUNT‑OSA trials, breathing problems during sleep started to get better after just four weeks, but the drug showed a clear advantage over placebo only after about five months. The bigger the weight loss, the bigger the improvement in sleep‑breathing measures.
Big studies show that the drug tirzepatide, especially at the 15 mg dose, can cut body weight by around 10 kg in people with diabetes and up to 21% in those without diabetes, making it one of the strongest weight‑loss tools we know of. It works about as well as the high‑dose version of semaglutide, but both cause more stomach upset than a placebo, while serious risks like pancreatitis stay low.
Tirzepatide, a new peptide drug, can cut body weight by about 22% in people without diabetes and around 15% in those with diabetes, but the loss tends to come back if you stop the drug. It’s generally safe, with stomach‑related side effects that usually ease after a few weeks, and long‑term heart‑benefit data are still missing.
Guo. Lixin L; Dong. Xiaolin X; Ma. Jianhua J; Liu. Ming M; Lu. Yibing Y; Wang. Hongman H; Li. Qingju...
In a 40‑week Chinese trial, adding the once‑weekly peptide tirzepatide to basal insulin slashed blood‑sugar (HbA1c) by about 2.4% on average, far more than the ~0.9% drop seen with placebo. The effect was similar at the 10 mg and 15 mg doses. The main side‑effects were mild‑to‑moderate gut issues like diarrhea, nausea and reduced appetite, which occurred more often than with placebo but were usually manageable.
Bracchiglione. Javier J; Meza. Nicolás N; Franco. Juan Va JV; Escobar Liquitay. Camila Micaela...
Semaglutide, a GLP‑1 drug, cuts body weight by about 10% after 6‑12 months and keeps that loss for up to two years, but it can cause more side‑effects that sometimes make people stop the drug; its impact on heart attacks, death and quality of life is modest and uncertain.
Figard. Camille C; Ben Messaoud. Raoua R; Baillieul. Sébastien S; Joyeux-Faure. Marie M; Destor...
This review looked at many studies on sleep‑apnoea treatments and found that while CPAP is still the top way to cut the number of breathing pauses, the diabetes drug tirzepatide also cuts those events by a lot and has solid evidence behind it. Exercise boosts quality of life the most, and most other options help daytime sleepiness. However, long‑term safety and how well people stick with these treatments need more research.
Mifsud. Caroline S CS; Kolla. Bhanu Prakash BP; Rushlow. David R DR; Mansukhani. Meghna P MP
Tirzepatide, a drug already used for weight loss, just got FDA approval to treat obstructive sleep apnea. This moves the focus from just using a CPAP machine to also targeting the underlying weight and metabolism that drive the breathing problem. The drug may help by shrinking fat around the airway and possibly by directly improving breathing, but the exact mix of effects isn’t fully known yet.
In three people who used tirzepatide (or semaglutide) for weight loss, those who added regular resistance training and ate enough protein kept or even added muscle while dropping fat. This shows you can lose weight with these drugs without losing lean tissue if you train hard and hit protein targets.
A big analysis of 91 trials found that the highest dose of tirzepatide (15 mg per week) more than doubled the chance of getting a gynecologic tumor, especially inside the uterus, compared to not using the drug. Even the lower 5 mg dose showed a similar jump in uterine tumor risk. No other GLP‑1 or SGLT2 drugs showed this problem.
Shokravi. Arveen A; Seth. Jayant J; Lu. Nelson N; Mancini. G B John GBJ
The meta‑analysis shows that drugs that act like gut hormones – including tirzepatide – cut heart‑related deaths, overall deaths, heart attacks and kidney problems in people with chronic kidney disease and type‑2 diabetes, and they also lower heart‑failure hospital visits in obese patients with a type of heart failure called HFpEF. While SGLT2 inhibitors may be a bit stronger for some outcomes, tirzepatide still offers solid cardio‑renal protection and big weight‑loss benefits, making it a useful tool for biohackers focused on longevity and metabolic health.
GLP‑1 drugs, originally for diabetes, also protect the heart and brain by cutting heart attacks, strokes, and heart‑failure events. New studies (SELECT) show they work even in non‑diabetic people who are overweight and have heart disease, and the newer dual‑action drug tirzepatide further lowers major cardiovascular events. However, they’re pricey and long‑term safety isn’t fully known, so careful use is advised.
Tan. Yee Wen YW; Shang. Mengge M; Davis. Sean S; Gananadha. Sivakumar S
This review shows that adding tirzepatide, a newer GLP‑1/GIP drug, after weight‑loss surgery can boost weight loss and improve blood sugar, blood pressure, and cholesterol, with mostly mild stomach side effects. It worked better than older drugs like semaglutide and liraglutide, especially for people who didn’t lose enough weight or regained weight after surgery.
Bayoumy. Ahmed B AB; Clarke. Lindsay M LM; Deepak. Parakkal P; Desai. Aakash A; Sehgal. Priya P; Gor...
A review of 11 studies shows that people with inflammatory bowel disease (IBD) who are also overweight can lose a lot of weight with drugs like tirzepatide (about 12 kg in three months) and may need fewer surgeries or hospital stays. The data are promising but still need solid clinical trials to confirm the benefits.